Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences
Date:12/3/2010

MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.The conference presentation schedule is as follows:Canaccord Genuity Cardiovascular, Diabetes & Obesity ConferenceDecember 8, 2010 at 12:30 p.m. PTNikko Hotel, San Francisco, CAPresenter: Charles Bowden, MD, director of clinical development2010 Deutsche Bank BioFEST ConferenceDecember 14, 2010 at 4:05 p.m. ETFour Seasons Hotel, Boston, MAPresenter: Timothy Morris, chief financial officerA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:   VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
7. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
8. VIVUS Announces Sale of MUSE Assets to Meda
9. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
10. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... multi-year, multi-hospital retrospective database analysis,demonstrates RDS treatment ... improved neonatal,survival --, NAPA, Calif. and PARMA, ... today at the Pediatric Academic Societies' Annual ... Syndrome (RDS) have a nearly 20% better ...
... Inspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results ... epinastine nasal,spray and placebo in patients with ... improvement in total nasal symptom score,dose-related effects ... higher,dose (0.1%) achieving statistical superiority over placebo., ...
Cached Medicine Technology:Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 2Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 3Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 4Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 5Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... has been effective for inoperable liver cancer. It is a year since ... a 25 ... rate in either reducing tumour size or the number of tumours. Till ... tumours, who cannot be treated by any other means. ,TheraSphere ...
... who suffer from dementia benefit from music therapy. The therapy ... The trials have found that the therapy is popular with ... at Imperial College London are planning to carry out a ... has long term benefits for dementia sufferers. If their results ...
... with low birth weight can significantly improve survival rates, ... diseases. The research involved 1,154 full-term but smaller than ... 5 1/2 pounds or less. Mothers fed them supplements ... the 20 who died had not been receiving zinc ...
... sole franchisee for US based Medicine Shoppe International, with operations ... from list of its target for operations in the country. ... to expand its franchisee operations from the present 19 outlets ... has decided to put on hold the commencing of operations ...
... a heavy breakfast and a steaming cup of tea may increase ... fried food each morning are at twice the risk of ... to reduce the incidence of cancer is to begin the day ... ,Cancer of the oesophagus - the food pipe connecting the stomach ...
... are more likely to get diagnosed with the progressive brain ... the case, although some have suggested that the disease may ... before it manifests itself elsewhere. ,Dr Robert Abbott, ... effectively identify people with early or suspected disease or people ...
Cached Medicine News:Health News:Cut down on fries 2